Eli Lilly and Company (NYSE:LLY) Shares Purchased by Bouvel Investment Partners LLC

Bouvel Investment Partners LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 1.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,644 shares of the company’s stock after buying an additional 106 shares during the period. Eli Lilly and Company makes up about 1.8% of Bouvel Investment Partners LLC’s holdings, making the stock its 18th biggest holding. Bouvel Investment Partners LLC’s holdings in Eli Lilly and Company were worth $5,129,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Beck Bode LLC acquired a new stake in Eli Lilly and Company during the 2nd quarter valued at approximately $15,036,000. Glass Jacobson Investment Advisors llc grew its position in shares of Eli Lilly and Company by 8.2% during the second quarter. Glass Jacobson Investment Advisors llc now owns 357 shares of the company’s stock worth $323,000 after buying an additional 27 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Eli Lilly and Company during the second quarter worth approximately $546,000. Intech Investment Management LLC raised its holdings in Eli Lilly and Company by 4.6% in the second quarter. Intech Investment Management LLC now owns 229,995 shares of the company’s stock valued at $208,233,000 after acquiring an additional 10,215 shares in the last quarter. Finally, Brighton Jones LLC boosted its stake in Eli Lilly and Company by 0.4% during the 2nd quarter. Brighton Jones LLC now owns 11,497 shares of the company’s stock valued at $10,409,000 after acquiring an additional 49 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LLY. Deutsche Bank Aktiengesellschaft cut their target price on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Wolfe Research began coverage on Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price objective on the stock. Barclays decreased their target price on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Bank of America reissued a “buy” rating and set a $997.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Finally, Citigroup boosted their target price on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research note on Friday, October 25th. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,002.22.

Eli Lilly and Company Stock Down 4.1 %

Shares of Eli Lilly and Company stock opened at $726.24 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a 1-year low of $612.70 and a 1-year high of $972.53. The business’s fifty day moving average price is $783.25 and its two-hundred day moving average price is $856.02. The company has a market capitalization of $689.43 billion, a P/E ratio of 78.51, a PEG ratio of 1.66 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The company had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. Eli Lilly and Company’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 earnings per share. As a group, research analysts forecast that Eli Lilly and Company will post 13.14 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.83%. The ex-dividend date is Friday, February 14th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 56.22%.

Eli Lilly and Company declared that its board has authorized a stock buyback plan on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to buy up to 2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.13% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.